Grifols SA
GRFS Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$8.10
KIRA · Stoqly’s AI analyst, in plain words
- Grifols SA had $8.5B of revenue in fiscal 2025, up 8.7% on the year before. Over five years, revenue changed +6.9% a year on average.
- Its operating margin was 16.5%, down 0.0 pts: of every 100 in sales, about 17 is left after running the business.
- Grifols SA made $453M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −3.1% a year.
- Free cash flow was $882M in fiscal 2025, 10.4% of revenue.
- Grifols SA returned $144M to shareholders in fiscal 2025, 16% of free cash flow. The diluted share count rose 0.2%.
- Grifols SA owes $1.6B more than it holds in cash, about 0.8 years of operating profit.
Market cap
—
P/E
—
Revenue
$8.5B
Net income
$453M
Free cash flow
$882M
Operating margin
16.5%
Grifols SA in 30 seconds · fiscal 2025
Are sales growing?
+8.7%
Yes. Sales grew 8.7% last year.
Does it make a profit?
5.3%
A little. It keeps 5.3% of every sale as profit.
Does profit turn into cash?
10.4%
Yes. 10.4% of sales ends up as free cash.
Is debt under control?
0.8x
Yes. It could repay its debt with 0.8 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
What Grifols SA does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 17, 2026
- Legal name
- Grifols SA
- CIK
- 0001438569
Grifols SA · GRFS · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $5.8B | $6.4B | $7.1B | $7.8B | $8.5B |
| Revenue growth | −4.1% | 9.2% | 11.9% | 9.4% | 8.7% |
| Gross margin | 39.8% | 36.5% | 37.7% | 38.7% | 38.0% |
| Operating margin | 12.1% | 12.9% | 11.9% | 16.5% | 16.5% |
| Net income | $223M | $194M | $45.4M | $170M | $453M |
| Net margin | 3.8% | 3.1% | 0.6% | 2.2% | 5.3% |
| Diluted EPS | $0.33 | $0.28 | $0.06 | $0.25 | $0.67 |
| Cash | |||||
| Cash from operations | $706M | −$1.5M | $235M | $976M | $1.2B |
| Capital expenditure | $293M | $298M | $242M | $252M | $299M |
| Free cash flow | $413M | −$300M | −$7.6M | $724M | $882M |
| FCF margin | 7.1% | −4.7% | −0.1% | 9.3% | 10.4% |
| Dividends paid | $296M | $0.6M | $0.0M | $1.1M | $144M |
| Share buybacks | $149M | $3.6M | $0.0M | — | — |
| Share count change | −0.5% | −0.3% | −0.3% | 0.4% | 0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $3.0B | $586M | $585M | $1.0B | $969M |
| Debt incl. finance leases | $374M | $3.8B | $4.0B | $2.4B | $2.5B |
| Shareholders' equity | $6.3B | $6.0B | $5.9B | $6.1B | $6.2B |
| Net debt / EBITDA | −2.4x | 2.6x | 2.6x | 0.8x | 0.8x |
| Current ratio | 1.6x | 2.3x | 2.6x | 2.7x | 2.5x |
| Interest coverage | 2.2x | 1.6x | 1.3x | 1.7x | 2.0x |
| Returns and quality | |||||
| Return on capital | 14.8% | 6.5% | 7.1% | 11.1% | 14.7% |
| Return on equity | 3.6% | 3.2% | 0.8% | 2.8% | 7.4% |
| Piotroski F-score | 5 | 4 | 7 | 8 | 5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Grifols SA · GRFS · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.10 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001438569). Latest version: stoqly.net/companies/grfs. Data updated November 1, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.